LUCD (Lucid Diagnostics) Selling and Marketing Expense: $ Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LUCD Lucid Diagnostics Inc LUCD
16 GF Score
Price $0.79
GF Value $0.73
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Lucid Diagnostics Selling and Marketing Expense?

Lucid Diagnostics LUCD +0.70% 16 Selling and Marketing Expense is $ Mil as of Jun. 2026. GuruFocus rates LUCD with a GF Score™ of 16/100 and a GF Value™ of $0.73 (Fairly Valued). The stock has 5 warning signs investors should review.

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Lucid Diagnostics's Selling and Marketing Expense for the three months ended in Jun. 2026 was $ Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2026 was $ Mil.

Lucid Diagnostics Selling and Marketing Expense Related Terms

Lucid Diagnostics Selling and Marketing Expense Historical Data

* Premium members only.

The historical data trend for Lucid Diagnostics's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucid Diagnostics Selling and Marketing Expense Chart

Lucid Diagnostics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling and Marketing Expense
Get a 7-Day Free Trial - - - - -

Lucid Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
LUCD
16GF Score
Lucid Diagnostics Inc LUCD
Selling and Marketing Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lucid Diagnostics Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling and Marketing Expense of $ Mil mean?
Lucid Diagnostics (LUCD) has a Selling and Marketing Expense of $ Mil as of Jun. 2026. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on Lucid Diagnostics and its competitors.
Is Lucid Diagnostics' Selling and Marketing Expense too high?
Lucid Diagnostics' current Selling and Marketing Expense is $ Mil. Overall, Lucid Diagnostics has a GF Score™ of 16/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Selling and Marketing Expense compare to QSI and STIM?
Lucid Diagnostics' Selling and Marketing Expense of $ Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling and Marketing Expense for a Medical Devices & Instruments company?
A good Selling and Marketing Expense depends on the Medical Devices & Instruments industry context. However, Selling and Marketing Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling and Marketing Expense mean?
A high Selling and Marketing Expense can signal that a stock is expensive relative to its fundamentals. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on Lucid Diagnostics and its competitors. Lucid Diagnostics's current Selling and Marketing Expense is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Fairly Valued. The stock's GF Value™ is $0.73, compared to a current price of $0.79 — trading 8.1% above its estimated fair value. The current Selling and Marketing Expense is $ Mil. Lucid Diagnostics' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling and Marketing Expense calculated?
Selling and Marketing Expense is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Selling and Marketing Expense is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lucid Diagnostics (LUCD) Overvalued in 2026?

Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued. The current stock price of $0.79 is trading 8.1% above its estimated GF Value™ of $0.73. GuruFocus considers Lucid Diagnostics to be Fairly Valued.

Key valuation signals for LUCD:

  • Selling and Marketing Expense: $ Mil
  • GF Value™: $0.73 vs. price of $0.79 (8.1% above fair value)
  • GF Score™: 16/100 with 5 warning signs

No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lucid Diagnostics Business Description

Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
16GF Score

Get the complete analysis for LUCD

Selling and Marketing Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.79
Price
$0.73
GF Value